Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Sepracor-Looks very promising -- Ignore unavailable to you. Want to Upgrade?

To: Andreas Helke who wrote (2775)	5/14/1999 6:32:00 PM
From: Don Miller	Read Replies (2) \| Respond to of 10280

THE GOOD NEWS, IMHO, IS CLINICAL DATA IS RELEASED TO WEB BEFORE CALL! IMHO JNJ has money problems, two deals dead in less than two weeks. The wrong Stock dropped. __________________________________________ SEPRACOR TO HOST CONFERENCE CALL TO DISCUSS NORASTEMIZOLE PRODUCT FRIDAY, MAY 14, 1999 5:54 PM EST - PRNewswire MARLBOROUGH, Mass., May 14 /PRNewswire/ -- Sepracor Inc. (Nasdaq:SEPR) today announced that the Company will host a conference call Monday, May 17th at 8:30 a.m. EST. The call in number is 800-230-1059 (USA) and 612-332-1210 (International). The replay number is 800-475-6701 (USA) and 320-365-3844 (International) access code 450450 and will be available after 12:00 p.m. EST. Norastemizole clinical data can be accessed at www.sepracor.com beginning Monday, May 17th prior to the conference call. To receive a copy of this release or recent releases via fax, call Sepracor's automated new fax line at 1-800-758-5804 ext. 780960. SOURCE Sepracor Inc. 05/14/99 /CONTACT: David P. Southwell, Chief Financial Officer, or Jonae R. Barnes, Executive Director, Investor Relations of Sepracor Inc., 508-481-6700/ /Company News On-Call: prnewswire.com or fax, 800-758-5804, ext. 780960/ /Web site: sepracor.com (SEPR) CO: Sepracor Inc. ST: Massachusetts IN: MTC SU: